Skip to main content

Rotator Cuff Tendinopathy

2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
2
SecukinumabPhase 3Monoclonal Antibody1 trial
SecukinumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT05758415Terminated60Est. Dec 2024
NCT05722522Terminated33Est. Dec 2024
CTM Biomedical
CTM BiomedicalON - Toronto
1 program
celgeneN/A1 trial
Active Trials
NCT06712290Withdrawn0Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
SandozSecukinumab
SandozSecukinumab
CTM Biomedicalcelgene

Clinical Trials (3)

Total enrollment: 93 patients across 3 trials

NCT05722522SandozSecukinumab

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Start: Aug 2023Est. completion: Dec 202433 patients
Phase 3Terminated
NCT05758415SandozSecukinumab

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Start: Aug 2023Est. completion: Dec 202460 patients
Phase 3Terminated
NCT06712290CTM Biomedicalcelgene

Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy

Start: Nov 2024Est. completion: Dec 20250
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.